This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Olanzapine and the New Generation of Antipsychotic Agents: Patterns of Use

William M. Glazer, M.D.

Published: April 1, 1997

Article Abstract

As the new generation of atypical antipsychotics becomes available, the limitations of the oldertypical agents become apparent. The new medications, which have benefits other than the alleviationof positive symptoms of schizophrenia, may also be beneficial for psychotic disorders that have respondedpoorly to conventional neuroleptics. This article will describe the potential use of the atypicalantipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depressionand mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders,dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patientswith mental retardation or developmental delays.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 58

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...